News
AKBA
1.390
-10.32%
-0.160
Akebia Therapeutics announces annual shareholder meeting via webcast
PUBT · 19h ago
Akebia doses first participants in AKB-9090 trial
TipRanks · 3d ago
Akebia doses first participants in Phase 1 trial of AKB-9090 for acute kidney injury
PUBT · 3d ago
Akebia Therapeutics Doses First Patient In Phase 1 Clinical Study Of AKB-9090 To Treat Cardiac Surgery-Associated Acute Kidney Injury
Benzinga · 3d ago
AKEBIA THERAPEUTICS ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1 CLINICAL TRIAL OF AKB-9090
Reuters · 3d ago
AKEBIA THERAPEUTICS INC - TOP LINE DATA FROM PHASE 1 TRIAL EXPECTED IN EARLY 2027
Reuters · 3d ago
AKEBIA THERAPEUTICS INC - AKB-097 TO ENTER PHASE 2 BASKET TRIAL IN RARE KIDNEY DISEASES IN SECOND HALF OF 2026
Reuters · 3d ago
Weekly Report: what happened at AKBA last week (0406-0410)?
Weekly Report · 3d ago
Akebia executives hold investor meetings at Raymond James Biotech Innovation Symposium
Reuters · 04/07 16:35
Akebia (AKBA): Buy Rating Backed by Vafseo Momentum and High-Value Renal Pipeline Upside
TipRanks · 04/07 10:35
Akebia Therapeutics Price Target Maintained With a $4.00/Share by BTIG
Dow Jones · 04/07 10:16
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
Benzinga · 04/07 10:05
Piper Sandler Sticks to Their Buy Rating for Akebia Therapeutics (AKBA)
TipRanks · 04/06 10:57
H.C. Wainwright Keeps Their Buy Rating on Akebia Therapeutics (AKBA)
TipRanks · 04/06 10:36
Weekly Report: what happened at AKBA last week (0330-0403)?
Weekly Report · 04/06 09:48
Akebia Therapeutics director Philip J. Vickers files initial beneficial ownership statement
Reuters · 04/03 20:06
Akebia names Philip Vickers to board of directors
Reuters · 04/01 20:06
AKEBIA THERAPEUTICS APPOINTS BIOPHARMACEUTICAL LEADER PHILIP VICKERS, PH.D. TO ITS BOARD OF DIRECTORS
Reuters · 04/01 20:05
Press Release: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
Dow Jones · 04/01 20:05
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
Barchart · 04/01 15:05
More
Webull provides a variety of real-time AKBA stock news. You can receive the latest news about Akebia Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.